Plasmid-based CRISPR-Cas9 system efficacy for introducing targeted mutations in CD81 gene of MDA-MB-231 cell line
, 1, 2, 1, 31
Abstract
Introduction. Breast cancer has been represented a challenging issue worldwide as it is one of the major leading causes of death among women. CD81 gene, a member of the tetraspanin protein family, has been associated with the development of human cancers. Genome editing technologies, particularly the CRISPR-Cas9 system, have shown rapid progress in gene function studies. In this study, we aimed to evaluate the ability of the CRISPR-Cas9 plasmid-based system to modify specific regions of the CD81 gene in the MDA-MB-231 breast cancer cell line. Materials and methods. Using bioinformatics database search, four different single guide RNAs (sgRNAs) to target exon 3 and exon 5 of the CD81 gene were designed. The intended sgRNAs sequences were cloned into the expression plasmid pSpCas9(BB)-2A-GFP (PX458) bearing sgRNA scaffold backbone, Cas9, and EGFP coding sequences, which was confirmed by colony PCR and sequencing. Transfection efficiency was determined by fluorescence microscopy and flow cytometry analysis. Gene editing efficiency was measured qualitatively and quantitatively using the T7E1 and TIDE software, respectively. Results. Our data show that expression constructs were successfully introduced into MDA-MB-231 cells with an acceptable transfection efficiency. Two sgRNAs that were afforded to introduce significant mutations in their target regions were detected by TIDE software (p-value < 0.05). To the best of our knowledge, CD81 gene editing in these cells has been investigated for the first time in this study using the CRISPR/Cas9 technique. Conclusions. Taken together, our data show that the CRISPR-Cas9 system can change the genomic sequence in the target area of MDA-MB-231 cells. Along with previous studies, we propose forethought when using T7E1-based quantitative indel estimates, as comparing activities of multiple gRNAs with the T7E1 assay may lead to inaccurate conclusions. Instead, estimating non-homologous end-joining events (NHEJ) by Sanger sequencing and subsequent TIDE analysis is recommended.
Keywords: CRISPR-Cas9gene editingCD81 geneMDA-MB-231 cellstransfection efficiency
References
- Bilani N, Zabor EC, Elson L, et al. Breast Cancer in the United States: A Cross-Sectional Overview. J Cancer Epidemiol. 2020; 2020: 6387378.
- Al-Mahmood S, Sapiezynski J, Garbuzenko OB, et al. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018; 8(5): 1483–1507.
- Tsang J, Tse G. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2019; 27(1): 27–35.
- Dai X, Cheng H, Bai Z, et al. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017; 8(16): 3131–3141.
- Sporikova Z, Koudelakova V, Trojanec R, et al. Genetic Markers in Triple-Negative Breast Cancer. Clin Breast Cancer. 2018; 18(5): e841–e850.
- Oren R, Takahashi S, Doss C, et al. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol. 1990; 10(8): 4007–4015.
- Termini CM, Gillette JM. Tetraspanins Function as Regulators of Cellular Signaling. Front Cell Dev Biol. 2017; 5: 34.
- Schaper F, van Spriel AB. Antitumor Immunity Is Controlled by Tetraspanin Proteins. Front Immunol. 2018; 9: 1185.
- Maecker HT, Levy S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med. 1997; 185(8): 1505–1510.
- Miyazaki T, Müller U, Campbell KS. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J. 1997; 16(14): 4217–4225.
- Vences-Catalán F, Kuo CC, Rajapaksa R, et al. CD81 is a novel immunotherapeutic target for B cell lymphoma. J Exp Med. 2019; 216(7): 1497–1508.
- Wang HX, Sharma C, Knoblich K, et al. EWI-2 negatively regulates TGF-β signaling leading to altered melanoma growth and metastasis. Cell Res. 2015; 25(3): 370–385.
- Küppers R. CD81 as target for B cell lymphomas. J Exp Med. 2019; 216(7): 1469–1470.
- Vences-Catalán F, Duault C, Kuo CC, et al. CD81 as a tumor target. Biochem Soc Trans. 2017; 45(2): 531–535.
- Jamehdor S, Zaboli KA, Naserian S, et al. An overview of applications of CRISPR-Cas technologies in biomedical engineering. Folia Histochem Cytobiol. 2020; 58(3): 163–173.
- Nargesi S, Kaboli S, Thekkiniath J, et al. Recent Advances in Genome Editing Tools in Medical Mycology Research. J Fungi (Basel). 2021; 7(4).
- Ballios BG, Pierce EA, Huckfeldt RM. Gene editing technology: Towards precision medicine in inherited retinal diseases. Semin Ophthalmol. 2021; 36(4): 176–184.
- Das BD, Paudel N. A Review on Reliability and Validity of CRISPR/Cas9 Technology for Gene Editing. Jordan J Biol Sci. 2021; 14(03): 503–511.
- Hendriks D, Clevers H, Artegiani B. CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids. Cell Stem Cell. 2020; 27(5): 705–731.
- Khodadad N, Fani M, Jamehdor S, et al. A knockdown of the herpes simplex virus type-1 gene in all-in-one CRISPR vectors. Folia Histochem Cytobiol. 2020; 58(3): 174–181.
- Zhang Ju, Cui ML, Nie YW, et al. CRISPR/Cas9-mediated specific integration of fat-1 at the goat MSTN locus. FEBS J. 2018; 285(15): 2828–2839.
- Sasano Yu, Nagasawa K, Kaboli S, et al. CRISPR-PCS: a powerful new approach to inducing multiple chromosome splitting in Saccharomyces cerevisiae. Sci Rep. 2016; 6: 30278.
- Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8(11): 2281–2308.
- Babon JJ, McKenzie M, Cotton RGH, et al. The use of resolvases T4 endonuclease VII and T7 endonuclease I in mutation detection. Methods Mol Biol. 2000; 152(1): 187–199.
- Jiang C, Meng L, Yang B, et al. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment. Clin Genet. 2020; 97(1): 73–88.
- Liu Y, Zeng Y, Liu Li, et al. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nat Commun. 2014; 5: 5393.
- García-Tuñón I, Alonso-Pérez V, Vuelta E, et al. Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency. PLoS One. 2019; 14(5): e0216674.
- Quagliano A, Gopalakrishnapillai A, Kolb EA, et al. CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia. Blood Adv. 2020; 4(18): 4393–4405.
- Montague TG, Cruz JM, Gagnon JA, et al. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 2014; 42(Web Server issue): W401–W407.
- Mizoshiri N, Shirai T, Terauchi R, et al. The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma. Cell Oncol (Dordr). 2019; 42(6): 861–871.
- Kim S, Kim D, Cho SW, et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014; 24(6): 1012–1019.
- Liu C, Zhang Li, Liu H, et al. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 2017; 266: 17–26.
- Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014; 383(9911): 60–68.
- Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369(9): 819–829.
- Mali P, Aach J, Stranges PB, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9): 833–838.
- Cong Le, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121): 819–823.
- Brinkman EK, Chen T, Amendola M, et al. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014; 42(22): e168.
- Sentmanat MF, Peters ST, Florian CP, et al. A Survey of Validation Strategies for CRISPR-Cas9 Editing. Sci Rep. 2018; 8(1): 888.
